2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Omics Technologies, Bioinformatics, Computational Biology, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Apoptosis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5010 An isogenic HL-60 resource reveals drug-specific resistance spectra, salvage liabilities, and an AZA-resistant monocytic state in AML

Zhe Wang, MD, PhD, Yue Shang2, Xinran Mi3, Ting Liu4, Qishan Hao5, Yang Song6, Yannan Jia7, Mutian Tang, BSc8, Zheng Tian9, Min Wang, PhD10, Yingchang Mi, MD11
1 Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States, National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
2 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
3 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
4 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
5 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China, The Affiliated Yantai Yuhuangding Hospital of Qingdao University,, Yantai, China
6 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
7 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 Division of Biomedical Informatics, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States, Division of Immunobiology, Cincinnati Children’s Hospital Medical Center, Cincinnati, Ohio, United States
9 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
10 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China
11 National Clinical Research Center for Blood Diseases. State Key Laboratory of Experimental Hematology. Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Tianjin, China

Cytarabine (Ara-C) and the hypomethylating agents (HMAs) decitabine (DEC) and azacitidine (AZA) remain the backbone of AML therapy, yet acquired resistance to each is usually studied in unrelated cell lines or inferred from heterogeneous patient cohorts, so drug-selection history cannot be separated from genetic background. To address this, we derived Ara-C-resistant (Ara-C-Re), DEC-resistant (DEC-Re), and AZA-resistant (AZA-Re) sublines from a single parental HL-60 culture by response-guided dose escalation. Each subline shifted markedly toward its selecting agent, remained proliferative on selecting-agent rechallenge after a drug-free stability interval, and showed state-specific cell-cycle and apoptotic behavior, providing an isogenic panel for direct comparison of acquired resistance states.

RNA sequencing showed that the three states were separable. All shared a low-biosynthetic persistence core, with common depletion of MYC targets V1 and ribosome biogenesis, but differentially expressed gene burden rose from Ara-C-Re (1,528) to DEC-Re (2,760) to AZA-Re (4,302), with 535 shared and 368, 435, and 1,788 state-unique upregulated features. Ara-C-Re added inflammatory and adhesion/migration programs, whereas AZA-Re showed the broadest suppression of MTORC1 and cytoplasmic translation. EPIC methylation profiling separated two architectures. DEC-Re and AZA-Re were globally hypomethylated (mean beta 0.31 and 0.25 vs 0.70 in parental cells; >475,000 DMPs each), whereas Ara-C-Re retained near-parental methylation with focal silencing. Promoter-DMR/RNA integration resolved the outputs of that shared background: DCK was promoter-hypermethylated and repressed in Ara-C-Re and DEC-Re but not AZA-Re; 870 promoter-hypomethylated, RNA-upregulated genes were shared by both HMA-resistant lines and enriched for leukocyte migration (FDR = 7.4 × 10-7); and 1,078 reactivated genes were AZA-Re-specific, including MAFB (delta-beta -0.623; log2FC +8.04) together with CD14, CD93, ITGAM, and S100A8/A9, defining a monocytic differentiation-like state unique to AZA selection.

Pharmacologic profiling of 38 single agents across 63 drug-concentration conditions and 20 fixed-dose combinations, with censor-aware IC50 estimation, mapped resistance spectra and salvage liabilities. Ara-C-Re and DEC-Re lost cytarabine activity, whereas AZA-Re retained 80.7% inhibition and preserved activity of all 14 cytarabine-containing regimens (74%-87% inhibition) despite losing AZA and DEC activity. DEC-Re uniquely retained 62%-67% inhibition with dasatinib, imatinib, and ponatinib within a receptor-kinase-high (higher KIT, FLT3, CSF1R, and FGR), oxidative state. In contrast, AZA-Re failed all three fixed-dose venetoclax (VEN) mixtures (VEN+DEC -1%, VEN+AZA -8%, VEN+LDAC 25%, vs 85%-98% in parental cells), linking its monocytic remodeling to VEN-based failure.

To test whether these states exist in patients, we used response-defined FIMM specimens, patient-deduplicated BeatAML Waves 1+2 and 3+4, and the independent HRA007413 resource. A four-gene receptor-kinase context score frozen from DEC-Re tracked ex-vivo dasatinib sensitivity in both BeatAML splits (Spearman rs = .238 and .210; q = .0011 and .049). For the AZA-Re state we fixed an equal-weight 18-gene score (Mono18) before any external evaluation; 16 of 18 genes were also promoter-hypomethylated and RNA-upregulated. Mono18 was coordinately upregulated in AZA-resistant and downregulated in Ara-C-resistant FIMM specimens (q = 7.3 × 10-8 and 2.1 × 10-6), was inversely associated with ex-vivo VEN sensitivity in all four resources (rs = -.369 to -.750; n = 96-169), and among 15 HRA007413 patients receiving VEN+AZA each 1-SD increase was associated with shorter overall survival (HR, 4.02; 95% CI, 1.25-12.94; P = .0196) and event-free survival (HR, 4.19; 95% CI, 1.42-12.37; P = .0096). Together these findings show that drug-selection history alone can generate divergent resistance architectures from one AML background, each with distinct salvage liabilities. Because AZA-Re arose from a clonal parental culture, AZA selection alone was sufficient to produce a monocytic, VEN-refractory state, supporting acquired HMA exposure as one route to the monocytic, VEN-resistant phenotype seen in patients. Fixed-dose results are preclinical and the 15-patient survival analysis exploratory; validating Mono18 will require larger treatment-annotated cohorts and orthogonal single-cell and in vivo approaches.

Zhe Wang, MD, PhD: No relevant conflicts of interest to declare.